Last reviewed · How we verify
Clopidogrel + ASA + Bivalirudin
This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events.
This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events. Used for Acute coronary syndrome with percutaneous coronary intervention, Prevention of stent thrombosis.
At a glance
| Generic name | Clopidogrel + ASA + Bivalirudin |
|---|---|
| Also known as | Plavix (clopidogrel), Aspirin (ASA), Angiomax (bivalirudin) |
| Sponsor | Juan J Badimon |
| Drug class | Antiplatelet agent + Anticoagulant combination |
| Target | P2Y12 receptor, cyclooxygenase, thrombin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a P2Y12 platelet inhibitor, ASA (aspirin) inhibits cyclooxygenase and platelet aggregation, and bivalirudin is a direct thrombin inhibitor. Together, they provide dual antiplatelet therapy plus anticoagulation, targeting multiple steps in the coagulation cascade to reduce thrombotic complications in acute coronary syndromes and percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome with percutaneous coronary intervention
- Prevention of stent thrombosis
Common side effects
- Bleeding
- Dyspnea
- Hypotension
- Thrombocytopenia
Key clinical trials
- Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers (PHASE4)
- Anticoagulant Treatments and Percutaneous Coronary Angioplasty (PHASE4)
- Simplified Anti-Thrombotic Therapy for FFR (NA)
- Antithrombotic Effects of Ticagrelor Versus Clopidogrel (PHASE4)
- Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI (PHASE4)
- Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance (PHASE4)
- A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel + ASA + Bivalirudin CI brief — competitive landscape report
- Clopidogrel + ASA + Bivalirudin updates RSS · CI watch RSS
- Juan J Badimon portfolio CI